The role of biochemical markers in the assessment of Non-alcoholic fatty liver disease in young Iraqi people


  • Shahad A. Qassam Department of Biochemistry, College of Medicine, University of Karbala, Karbala, Iraq.
  • Zaid K. Ahmed Department of Anatomy, College of Medicine, University of Karbala, Karbala, Iraq.
  • Shaymaa Z. Nada Department of Biochemistry, College of Medicine, University of Karbala, Karbala, Iraq.


Non-alcoholic Fatty Liver Disease, Non-alcoholic steatohepatitis, Keratin-18, Fatty liver index


Objectives: to study clinical diagnostic markers and prognostic biochemical markers which will help to evaluate of Nonalcoholic fatty liver disease in Iraqi Young adult.

Method: a total of 816 patients referred for ultrasound  checking, their aged (18-40) years they were studied to detect the prevalence of NAFLD. For comparison of level of CK18 and other studied markers, we choose 45 patients with NAFLD, From the remaining standard individuals, we randomly selected 45 individuals as control group. Blood sample was collected to measured lipid profile, liver enzyme and CK-18, Enzyme-linked immune sorbent assay (ELISA) used for detecting and quantifying inflammatory markers.

Results: show that serum CK-18 was highly significant in patient with non-alcoholic fatty liver disease when comparison with control groups (P = 0.001), also showed Fatty Liver Index (FLI) values were significantly higher in patient with NALD than in control group (P =0.001), showed markedly great diagnostic accuracy (AUROC curve: 0.968).

Conclusion, our result indicates from results of inflammatory markers most patients in this study with steatohepatitis, FLI is most sensitive diagnostic marker for diagnostic NAFLD.


1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55(6):2005±2023.
2. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010; 28:155±161.
3. Sanal MG. Biomarkers in nonalcoholic fatty liver disease the empero has no clothes? , World J Gastroenterol .2015;21(11),pp. 3223-3231 .
4. Xinhuan Wei, MM,a Hongshan Wei, MD,b Wei Lin, MM,a Zhongjie Hu, MD,a and Jing Zhang, MDa. Cell death biomarker M65 is a useful indicator of liver inflammation and fibrosis in chronic hepatitis B . Medicine (Baltimore).2017;96(20),pp. e6807.
5. Gian Paolo Caviglia1, Rinaldo Pellicano. Serum Cytokeratin-18 Levels for Liver Fibrosis Prediction , Hepat Mon.2015; 15(8),pp. e30853.
6. Huang, J.F., Yeh, M.L., Huang, C.F., Huang, C.I., Tsai, P.C., Tai, C.M., Yang, H.L., Dai, C.Y., Hsieh, M.H., Chen, S.C. and Yu, M.L. Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patients. PloS one.2017; 12(5), p.e0174394..
7. John Vizuete, Alfredo Camero, Mazyar Malakouti, Karthik Garapati1 and Julio Gutierrez,. Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies. Journal of Clinical and Translational Hepatology .2017;5(1),pp.67-75 .
8. Yuan-Lung Cheng, Yuan-Jen Wang, Keng-Hsin Lan, Teh-Ia Huo, Yi-Hsiang Huang, Chien-Wei Su, Wei-Yao Hsieh, Ming-Chih Hou, Han-Chieh Lin, Fa-Yauh Lee, Jaw-ChingWu, and Shou-Dong Lee. Fatty Liver Index and Lipid Accumulation Product Can Predict Metabolic Syndrome in Subjects without Fatty Liver Disease . Gastroenterology Research and Practice ,(2017),.2017; Article ID 9279836pp. 12 .
9. Agnieszka Zwolak, Agnieszka Szuster-Ciesielska, Jadwiga Daniluk, Justyna Semeniuk, Martyna Kandefer-Szerszen , Chemerin. Chemerin, retinol binding protein-4, cytokeratin-18 and transgelin-2 presence in sera of patients with non-alcoholic liver fatty disease. Annals of Hepatology: Official Journal of the Mexican Association of Hepatology.2016; 15(6) : 862-869 .
10. 10-Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L. and Wymer, M.. Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology.2016; 64(1), pp.73-84.
11. Michael H. Le, Pardha Devaki, Nghiem B. Ha, , Dae Won Jun5, Helen S. Te, Ramsey C. Cheung, Mindie H. Nguyen. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PloS one.2017; 12(3), p.e0173499.
12. Elizabeth M. Brun, Vincent W. S. Wong, Valerio Nobili, Christopher P. Day, Silvia Sookoian, Jacquelyn J. Maher, Elisabetta Bugianesi, Claude B. Sirlin, Brent A. Neuschwander-Tetri and Mary E. Rinella, Nonalcoholic fatty liver disease. Article number: 15080 17 December 2015 voume 1.
13. Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Digestive and Liver Disease.2017; 47(3), pp.181-190.
14. Than NN, Newsome PN. A concise review of non-alcoholic fatty liver disease. Atherosclerosis.2015; 239(1), pp.192-202.
15. Pappachan, J.M., Antonio, F.A., Edavalath, M. and Mukherjee, A. Non-alcoholic fatty liver disease: a diabetologist’s perspective. Endocrine.2014; 45(3), pp.344-353.
16. Hashimoto, E., Taniai, M. and Tokushige, K. Characteristics and diagnosis of NAFLD/NASH. Journal of gastroenterology and hepatology.2013; 28(S4), pp.64-70.
17. European Association for the Study of the Liver, European Association for theStudy of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fattyliver disease. Journal of Hepatology 2016; 64:1388–402.
18. Mohsen M. Maher , Wesam A. Ibrahim , Shereen A. Saleh , Lobna Shash , Hoda Abou Gabal , Mohammed Tarif , Mohammed Gamal.. Cytokeratin 18 as a non invasive marker in diagnosis of NASH and its usefulness in correlation with disease severity in Egyptian patients. Egyptian Journal of Medical Human Genetics, 2015; 16(1), pp.41-46.
19. Feldstein, A.E., Alkhouri, N., De Vito, R., Alisi, A., Lopez, R. and Nobili, V. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. The American journal of gastroenterology.2013; 108(9), pp.1526-1531.
20. Liang, J., Liu, F., Wang, F., Han, T., Jing, L., Ma, Z. and Gao, Y. A Noninvasive Score Model for Prediction of NASH in Patients with Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease. BioMed research international. 2017; 2017.
21. Cusi, K., Chang, Z., Harrison, S., Lomonaco, R., Bril, F., Orsak, B., Ortiz-Lopez, C., Hecht, J., Feldstein, A.E., Webb, A. and Louden, C. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. Journal of hepatology, 2014; 60(1), pp.167-174.
22. Fadhil Jawad Al-tuma, Hedef Dafer El-yassin and Kammela Hadi Shammam,. Alcohol dehydrogenase genotype (ADH2 and ADH3) in alcoholism of Iraqi people, J Cont Med Sci 2015, vol 1. No 2, pp:9-13.
23. Sviklāne L, Olmane E, Dzērve Z , Kupčs K, Pīrāgs V V, Sokolovska J. Fatty liver index and hepatic steatosis index predict non‐alcoholic fatty liver disease in type 1 diabetes. Journal of Gastroenterology and Hepatology .2017; doi: 10.1111/jgh.13814 . PMID: 28464337 .
24. Cuthbertson, D.J., Weickert, M.O., Lythgoe, D., Sprung, V.S., Dobson, R., Shoajee-Moradie, F., Umpleby, M., Pfeiffer, A.F., Thomas, E.L., Bell, J.D. and Jones, H. External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals. European journal of endocrinology. 2014; 171(5), pp.561-569.
25. Evangeline Vassilatou1, Sophia Lafoyianni2, Dimitra-Argyro Vassiliadi3, Dimitrios Ioannidis2, Stavroula Paschou1, Maria Mizamtzidi1 & Andromachi Vryonidou. Diagnostic performance of non-invasive markers for the presence of nonalcoholic fatty liver disease in premenopausal women with and without polycystic ovary syndrome.2017;49 EP1139 .
26. Kantartzis, K., Rettig, I., Staiger, H., Machann, J., Schick, F., Scheja, L., Gastaldelli, A., Bugianesi, E., Peter, A., Schulze, M.B. and Fritsche,. An extended fatty liver index to predict non-alcoholic fatty liver disease . Diabetes & Metabolism .2017;43(3), pp.229-239.
27. Huang, X., Xu, M., Chen, Y., Peng, K., Huang, Y., Wang, P., Ding, L., Lin, L., Xu, Y., Chen, Y. and Lu, J., 2015. Validation of the fatty liver index for nonalcoholic fatty liver disease in middle-aged and elderly Chinese. Medicine, 94(40). The FLI was suggested to be a useful noninvasive method for the diagnosis of NAFLD.
28. Motamed, N., Sohrabi, M., Ajdarkosh, H., Hemmasi, G., Maadi, M., Sayeedian, F.S., Pirzad, R., Abedi, K., Aghapour, S., Fallahnezhad, M. and Zamani, F., 2016. Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease. World journal of gastroenterology, 22(10), p.3023.




How to Cite

Qassam, S. A., Ahmed, Z. K., & Nada, S. Z. (2019). The role of biochemical markers in the assessment of Non-alcoholic fatty liver disease in young Iraqi people. Iraq Medical Journal, 3(2). Retrieved from